Aida Collado1,2, Patrice Marques1,2, Paula Escudero1,2, Cristina Rius1,2, Elena Domingo1, Sergio Martinez-Hervás2,3,4, José T Real2,3,4, Juan F Ascaso2,3,4, Laura Piqueras1,2, Maria-Jesus Sanz1,2. 1. Department of Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain. 2. Institute of Health Research INCLIVA, University of Valencia, Av. Menéndez Pelayo 4, Valencia, Spain. 3. Department of Medicine, Faculty of Medicine, Endocrinology and Nutrition Unit, University Clinic Hospital of Valencia, University of Valencia, Valencia, Spain. 4. CIBERDEM-Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders, ISCIII, Spain.
Abstract
Aims: Angiotensin-II (Ang-II) is the main effector peptide of the renin-angiotensin system (RAS) and promotes leucocyte adhesion to the stimulated endothelium. Because RAS activation and Ang-II signalling are implicated in metabolic syndrome (MS) and abdominal aortic aneurysm (AAA), we investigated the effect of Ang-II on CXCL16 arterial expression, the underlying mechanisms, and the functional role of the CXCL16/CXCR6 axis in these cardiometabolic disorders. Methods and results: Results from in vitro chamber assays revealed that CXCL16 neutralization significantly inhibited mononuclear leucocyte adhesion to arterial but not to venous endothelial cells. Flow cytometry and immunofluorescence studies confirmed that Ang-II induced enhanced endothelial CXCL16 expression, which was dependent on Nox5 up-regulation and subsequent RhoA/p38-MAPK/NFκB activation. Flow cytometry analysis further showed that MS patients had higher levels of platelet activation and a higher percentage of circulating CXCR6-expressing platelets, CXCR6-expressing-platelet-bound neutrophils, monocytes, and CD8+ lymphocytes than age-matched controls, leading to enhanced CXCR6/CXCL16-dependent adhesion to the dysfunctional (Ang-II- and TNFα-stimulated) arterial endothelium. Ang-II-challenged apolipoprotein E-deficient (apoE-/-) mice had a higher incidence of AAA, macrophage, CD3+, and CXCR6+ cell infiltration and neovascularization than unchallenged animals, which was accompanied by greater CCL2, CXCL16, and VEGF mRNA expression within the lesion together with elevated levels of circulating soluble CXCL16. Significant reductions in these parameters were found in animals co-treated with the AT1 receptor antagonist losartan or in apoE-/- mice lacking functional CXCR6 receptor (CXCR6GFP/GFP). Conclusion: CXCR6 expression on platelet-bound monocytes and CD8+ lymphocytes may constitute a new membrane-associated biomarker for adverse cardiovascular events. Moreover, pharmacological modulation of this axis may positively affect cardiovascular outcome in metabolic disorders linked to Ang-II.
Aims: Angiotensin-II (Ang-II) is the main effector peptide of the renin-angiotensin system (RAS) and promotes leucocyte adhesion to the stimulated endothelium. Because RAS activation and Ang-II signalling are implicated in metabolic syndrome (MS) and abdominal aortic aneurysm (AAA), we investigated the effect of Ang-II on CXCL16 arterial expression, the underlying mechanisms, and the functional role of the CXCL16/CXCR6 axis in these cardiometabolic disorders. Methods and results: Results from in vitro chamber assays revealed that CXCL16 neutralization significantly inhibited mononuclear leucocyte adhesion to arterial but not to venous endothelial cells. Flow cytometry and immunofluorescence studies confirmed that Ang-II induced enhanced endothelial CXCL16 expression, which was dependent on Nox5 up-regulation and subsequent RhoA/p38-MAPK/NFκB activation. Flow cytometry analysis further showed that MSpatients had higher levels of platelet activation and a higher percentage of circulating CXCR6-expressing platelets, CXCR6-expressing-platelet-bound neutrophils, monocytes, and CD8+ lymphocytes than age-matched controls, leading to enhanced CXCR6/CXCL16-dependent adhesion to the dysfunctional (Ang-II- and TNFα-stimulated) arterial endothelium. Ang-II-challenged apolipoprotein E-deficient (apoE-/-) mice had a higher incidence of AAA, macrophage, CD3+, and CXCR6+ cell infiltration and neovascularization than unchallenged animals, which was accompanied by greater CCL2, CXCL16, and VEGF mRNA expression within the lesion together with elevated levels of circulating soluble CXCL16. Significant reductions in these parameters were found in animals co-treated with the AT1 receptor antagonist losartan or in apoE-/- mice lacking functional CXCR6 receptor (CXCR6GFP/GFP). Conclusion:CXCR6 expression on platelet-bound monocytes and CD8+ lymphocytes may constitute a new membrane-associated biomarker for adverse cardiovascular events. Moreover, pharmacological modulation of this axis may positively affect cardiovascular outcome in metabolic disorders linked to Ang-II.
Authors: Weronika Zarychta-Wiśniewska; Anna Burdzińska; Katarzyna Zielniok; Marta Koblowska; Kamila Gala; Piotr Pędzisz; Roksana Iwanicka-Nowicka; Anna Fogtman; Aleksandra Aksamit; Agnieszka Kulesza; Aleksandra Zołocińska; Leszek Pączek Journal: Stem Cells Int Date: 2019-05-07 Impact factor: 5.443
Authors: Stefanie Lesch; Viktoria Blumenberg; Stefan Stoiber; Adrian Gottschlich; Justyna Ogonek; Bruno L Cadilha; Zahra Dantes; Felicitas Rataj; Klara Dorman; Johannes Lutz; Clara H Karches; Constanze Heise; Mathias Kurzay; Benjamin M Larimer; Simon Grassmann; Moritz Rapp; Alessia Nottebrock; Stephan Kruger; Nicholas Tokarew; Philipp Metzger; Christine Hoerth; Mohamed-Reda Benmebarek; Dario Dhoqina; Ruth Grünmeier; Matthias Seifert; Arman Oener; Öykü Umut; Sandy Joaquina; Lene Vimeux; Thi Tran; Thomas Hank; Taisuke Baba; Duc Huynh; Remco T A Megens; Klaus-Peter Janssen; Martin Jastroch; Daniel Lamp; Svenja Ruehland; Mauro Di Pilato; Jasper N Pruessmann; Moritz Thomas; Carsten Marr; Steffen Ormanns; Anna Reischer; Michael Hristov; Eric Tartour; Emmanuel Donnadieu; Simon Rothenfusser; Peter Duewell; Lars M König; Max Schnurr; Marion Subklewe; Andrew S Liss; Niels Halama; Maximilian Reichert; Thorsten R Mempel; Stefan Endres; Sebastian Kobold Journal: Nat Biomed Eng Date: 2021-06-03 Impact factor: 25.671
Authors: Sandra P Smieszek; Vasilios M Polymeropoulos; Christos M Polymeropoulos; Bartlomiej P Przychodzen; Gunther Birznieks; Mihael H Polymeropoulos Journal: Cytokine Date: 2022-01-31 Impact factor: 3.861
Authors: Lisa Schielke; Nick Zimmermann; Sarah Hobelsberger; Julian Steininger; Anne Strunk; Kristin Blau; Jessica Hernandez; Stephan Künzel; Robert Ziegenbalg; Sarah Rösing; Stefan Beissert; Susanne Abraham; Claudia Günther Journal: Front Immunol Date: 2022-06-17 Impact factor: 8.786